glp-1 ra cardiovascular benefits The effects of receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action Benefits of treatment with SGLT2i

cms.gov/medicare/coverage/prescription-drug-coverage/medicare-glp-1-bridge Kaiser Family Foundation

g , Schematic

Nauck has been member on advisory boards or has consulted with AstraZeneca, Boehringer Ingelheim, Eli Lilly & Co., GlaxoSmithKline, HoffmanLa Roche, Menarini/Berlin Chemie, Merck, Sharp & Dohme, NovoNordisk, Versatis

Diabetes Care (2016) 39(6):88492.10.2337/dc16-0351 140 ThazhathSSMaratheCSWuTChangJKhooJKuoPet alThe glucagon-like peptide 1 receptor agonist exenatide inhibits small intestinal motility, flow, transit, and absorption of glucose in healthy subjects and patients with type 2 diabetes: a randomized controlled trial

Furthermore, Gs activation can both enhance the Ca 2+ signal and increase the efficacy of the secretory machinery in intestinal L-cells 35

Ma L, Peng S, Wei J, Zhao M, Ahmad KA, Chen J, Wang YX